Alexion About
Alexion: Alexion is a new biopharmaceutical company committed
to developing a novel class of anti-inflammatory compounds, known as complement
inhibitors.Recent research provides new evidence that the Alexion's C5 inhibitors
may be a novel class of potent therapeutics able to prevent inflammation without
the general immunosuppression associated with current therapies. Complement
activation results in a unidirectional sequence of enzymatic and biochemical
reactions known as the complement cascade. The end result produces a number of
inflammatory byproducts, including injurious cytokines, inflammatory enzymes,
and cell adhesion molecules. These by products can lead to the destruction of
tissue seen in many inflammatory diseases. Alexion has combined its expertise
in immunobiology, clinical development, and human antibody engineering to enable
the development of a large array of monoclonal antibody and other recombinant
therapeutics targeting the treatment of a diverse collection of severe disease
states, including cardiovascular and autoimmune disorders, inflammation and cancer.
Pipeline: NIH
Trials for Pexelizumab (Coronary Heart Disease) Phase III NIH
Trials for Pexelizumab (Myocardial Infarction) Phase III
Pipeline
Chart
Phase
III Pexelizumab Cardiopulmonary
Bypass Phase
III Pexelizumab
Acute
Myocardial Infarction Phase
II Eculizumab Rheumatoid
Arthritis Phase
II Eculizumab
Nephritis
Phase
I Eculizumab
Dermatomyositis
Phase
I Eculizumab Paroxysmal
Nocturnal Hemoglinuria
More on Alexion: